$90MM in cash, $40 stock buy back program with $16MM left. While SCLN reduced 2012 revenues it'll still be more than 2011. SCLN's main driver is Zadaxin but has a promising pipeline.
The market cap is $240MM less cash leaves a value of $150MM, that is roughly 6 times earnings. SCLN is way oversold at $4.3 pps.